LATEST

• BUSINESS Nxera Files for Daridorexant Approval in South Korea
  March 5, 2026

• BUSINESS Sawai Prevails in Patent Suit against Viatris over Amitiza Generic
  March 5, 2026

• BUSINESS Kyowa Kirin Halts Rocatinlimab Clinical Trials on Malignancy Concerns
  March 4, 2026

• BUSINESS Meiji’s Morcamilast Wins EU Orphan Tag for Palmoplantar Pustulosis
  March 4, 2026

• BUSINESS Efient AGs Launched Just Ahead of 3-Month Supply Deadline
  March 4, 2026

• BUSINESS Takeda Targets Psoriasis Market with Zasocitinib, Touts Edge in TYK2 Selectivity
  March 4, 2026

• BUSINESS Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
  March 3, 2026

• BUSINESS Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
  March 3, 2026

• REGULATORY Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
  March 3, 2026

• BUSINESS UCB, Daiichi Sankyo to Wind Up Japan Partnership for Vimpat
  March 3, 2026

• REGULATORY MHLW Revises Guidance on Pediatric Development Plans under Amended PMD Act
  March 3, 2026

• REGULATORY MHLW Details New Operational Rules for Conditional Approvals from May
  March 3, 2026

• ACADEMIA Japan Begins Investigator-Led PII of Padcev in Small Bowel Adenocarcinoma
  March 3, 2026

• BUSINESS Itochu Snaps Up CoreMed to Bolster Japan Entry Support
  March 3, 2026

• BUSINESS Ono to Transfer Opalmon, Prostandin to Daito by November
  March 3, 2026

• BUSINESS Epadel Launched in Vietnam: Mochida/Meiji
  March 3, 2026

• BUSINESS Eisai, Merck File Lenvima-Welireg Combo for RCC in US
  March 3, 2026

• BUSINESS US FDA Accepts Takeda’s Rusfertide Filing, Grants Priority Review
  March 3, 2026

• ORGANIZATION EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
  March 2, 2026

• BUSINESS Ono, AstraZeneca to End Japan Co-Promotion of Forxiga
  March 2, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »